The alteration of fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?

Escape from the immune surveillance may play an important role in tumor outgrowth and metastasis. Alteration of the Fas receptor (Fas)/ligand (FasL) system including soluble forms is regarded as one of the mechanisms preventing the immune system from rejecting the tumor cells. However, less attention has been paid to the role of Fas/FasL interaction in vivo. Therefore, we investigated the expression of Fas and FasL by immunohistochemistry and reverse‐transcription polymerase chain reaction (RT‐PCR) and measured the serum levels of soluble Fas (sFas) and FasL (sFasL) in 44 patients with hepatocellular carcinoma (HCC). In the noncancerous liver tissues, Fas expression was up‐regulated in most cases, and FasL expression was detected in 6 cases. In Fas‐positive HCC cases (n = 15), the intrahepatic metastatic foci was less (P = .037), apoptosis of tumor cells was more (P = .004), the disease‐free survival rate was higher (P = .004), and p53‐positive cases were less (P = .003), compared with Fas‐negative cases. The sFas and sFasL levels in HCC patients were significantly higher and lower than those in controls, respectively. RT‐PCR and immunohistochemistry revealed generation of sFas in the hepatocytes and tumor‐infiltrating mononuclear cells rather than in hepatoma cells. Accordingly, hepatoma cells may eliminate Fas expression on themselves and let the hepatocytes and infiltrating mononuclear cells generate sFas to escape from the immune system and to produce metastasis. FasL might contribute to malignant transformation in some circumstances, because hepatocytes in the pericancerous pseudolobules expressed FasL.

[1]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[2]  P. Hainaut,et al.  Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. , 1998, Cancer research.

[3]  Matsunaga,et al.  Elevated serum levels of soluble Fas/APO‐1 (CD95) in patients with hepatocellular carcinoma , 1998, Clinical and experimental immunology.

[4]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[6]  T. Koike,et al.  Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases , 1997, Clinical and experimental immunology.

[7]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[8]  S. Nagata Fas ligand and immune evasion , 1996, Nature Medicine.

[9]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[10]  L. Owen-Schaub,et al.  Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. , 1996, Cancer research.

[11]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[12]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[13]  M. Mizumoto,et al.  Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential , 1996, Hepatology.

[14]  M. Kojiro,et al.  Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. , 1996, American Journal of Pathology.

[15]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[16]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[17]  P. Galle,et al.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.

[18]  M. Peter,et al.  APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. , 1995, International immunology.

[19]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[20]  J. Mountz,et al.  Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. , 1995, The Biochemical journal.

[21]  C. Ware,et al.  Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? , 1995, Cancer letters.

[22]  M. Weller,et al.  Fas/APO-1 gene transfer for human malignant glioma. , 1995, Cancer research.

[23]  J. Roth,et al.  Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression , 1995, Molecular and cellular biology.

[24]  G. Fiucci,et al.  Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. , 1995, Journal of immunology.

[25]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[26]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[27]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[28]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[29]  C. Smith,et al.  Fas ligand mediates activation-induced cell death in human T lymphocytes , 1995, The Journal of experimental medicine.

[30]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[31]  V. Zurawski,et al.  Apoptotic cell death induced by a mouse‐human anti‐APO‐1 chimeric antibody leads to tumor regression , 1994, International journal of cancer.

[32]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[33]  S. Yonehara,et al.  Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Ju,et al.  Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Koretz,et al.  Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.

[36]  I. Behrmann,et al.  Regulation of apoptosis in the immune system. , 1994, Current opinion in immunology.

[37]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[38]  L. Owen-Schaub,et al.  Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. , 1994, Cancer research.

[39]  P. Erb,et al.  Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. , 1994, Journal of immunology.

[40]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[41]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[42]  P. Golstein,et al.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.

[43]  M. Pawlita,et al.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. , 1992, The Journal of biological chemistry.

[44]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[45]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[46]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[47]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.